- Home
- RGC vs EARN Comparison
RGC vs EARN Comparison
Compare RGC & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | EARN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 169.8M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RGC | EARN |
|---|---|---|
| Price | $5.50 | $4.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 163.7K | ★ 397.9K |
| Earning Date | 10-31-2025 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $4.25 |
| 52 Week High | $69.00 | $5.81 |
Technical Indicators
Market Signals| Indicator | RGC | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 54.23 |
| Support Level | $4.91 | $4.29 |
| Resistance Level | $6.22 | $4.48 |
| Average True Range (ATR) | 0.39 | 0.06 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 48.16 | 82.35 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.